254 related articles for article (PubMed ID: 18434631)
1. Response evaluation of gastrointestinal stromal tumors.
Choi H
Oncologist; 2008; 13 Suppl 2():4-7. PubMed ID: 18434631
[TBL] [Abstract][Full Text] [Related]
2. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
3. The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
Van den Abbeele AD
Oncologist; 2008; 13 Suppl 2():8-13. PubMed ID: 18434632
[TBL] [Abstract][Full Text] [Related]
4. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
[TBL] [Abstract][Full Text] [Related]
5. Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
Shankar S; Dundamadappa SK; Karam AR; Stay RM; van Sonnenberg E
Acta Radiol; 2009 Oct; 50(8):837-44. PubMed ID: 19735005
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
7. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
Abhyankar SA; Nair N
Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851
[No Abstract] [Full Text] [Related]
8. CT evaluation of gastrointestinal stromal tumors treated with imatinib mesylate.
Erturk SM
AJR Am J Roentgenol; 2005 Nov; 185(5):1366; author reply 1366-7. PubMed ID: 16247167
[No Abstract] [Full Text] [Related]
9. Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.
Tirumani SH; Jagannathan JP; Hornick JL; Ramaiya NH
Clin Radiol; 2013 Aug; 68(8):e429-37. PubMed ID: 23622797
[TBL] [Abstract][Full Text] [Related]
10. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
11. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
[TBL] [Abstract][Full Text] [Related]
12. The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET.
Dietrich C; Hartung E; Ignee A
Ultraschall Med; 2008 Dec; 29 Suppl 5():276-7. PubMed ID: 19177288
[No Abstract] [Full Text] [Related]
13. [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors].
García-González J; Sánchez Salmón A; Areses Manrique C; León Mateos L; Barandela Salgado J; López López R
Rev Esp Med Nucl; 2007; 26(2):100-2. PubMed ID: 17386236
[TBL] [Abstract][Full Text] [Related]
14. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
Zincirkeser S; Sevinc A; Kalender ME; Camci C
World J Gastroenterol; 2007 Apr; 13(15):2261-2. PubMed ID: 17465516
[TBL] [Abstract][Full Text] [Related]
15. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
16. [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].
Simó Perdigó M; García Garzón JR; Soler Peter M; Pérez Moure G; López Gandul S; Lomeña Caballero FJ
Rev Esp Med Nucl; 2006; 25(2):80-8. PubMed ID: 16759613
[TBL] [Abstract][Full Text] [Related]
17. PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.
Gelibter A; Milella M; Ceribelli A; Zeuli M; Ferraresi V; Vecchione A; Cognetti F
Anticancer Res; 2004; 24(5B):3147-51. PubMed ID: 15510603
[TBL] [Abstract][Full Text] [Related]
18. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
[TBL] [Abstract][Full Text] [Related]
19. New strategies for treating GIST when imatinib fails.
Boyar MS; Taub RN
Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
[TBL] [Abstract][Full Text] [Related]
20. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
Holdsworth CH; Badawi RD; Manola JB; Kijewski MF; Israel DA; Demetri GD; Van den Abbeele AD
AJR Am J Roentgenol; 2007 Dec; 189(6):W324-30. PubMed ID: 18029844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
